Ambrx Biopharma Inc. to Present at the 30th Annual Virtual Credit Suisse Healthcare Conference
01 November 2021 - 9:05PM
Business Wire
Ambrx Biopharma Inc., or Ambrx (NYSE: AMAM), a clinical stage
biopharmaceutical company using an expanded genetic code technology
platform to create Engineered Precision Biologics, today announced
that Feng Tian, Ph.D., President and Chief Executive Officer of
Ambrx, will present at the 30th Annual Virtual Credit Suisse
Healthcare Conference on Monday, November 8th, 2021, at 4:20 PM
ET.
A live webcast of the presentation will be available online in
the “Investor Relations” section of the company’s website at
https://ir.ambrx.com/events-and-presentations/events/default.aspx.
A replay of the presentation will be available on the company
website for 90 days following the webcast.
About Ambrx Biopharma Inc. (Ambrx)
Ambrx is a clinical stage biopharmaceutical company using an
expanded genetic code technology platform to discover and develop
Engineered Precision Biologics. These include next generation
antibody drug conjugates (ADCs), bispecifics, targeted
immuno-oncology therapies, novel cytokines to modulate the immune
system, and long-acting therapeutic peptides for metabolic and
cardiovascular disease. Ambrx is advancing a robust portfolio of
clinical and preclinical programs designed to optimize efficacy,
safety and ease of use, in multiple therapeutic areas, including
its lead product candidate ARX788. In addition, Ambrx has clinical
collaborations, with multiple partners, for drug candidates
generated using Ambrx technology. For additional information,
please visit www.ambrx.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211101005848/en/
INVESTORS Laurence Watts Managing Director Gilmartin Group, LLC.
619-916-7620 ir@ambrx.com
MEDIA Ian Stone Managing Director Canale Communications (619)
849-5388 media@ambrx.com
Ambrx Biopharma (NYSE:AMAM)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Ambrx Biopharma (NYSE:AMAM)
Historical Stock Chart
Von Apr 2023 bis Apr 2024